为排卵诱导治疗无排卵性生育力低下正名
本文针对部分专家主张放弃排卵诱导作为无排卵性生育力低下首选治疗的观点进行论述。作者指出,在无其他不孕原因时,1型和2型无排卵患者行排卵诱导可达80%排卵率和40%累积妊娠率且不良反应少,而辅助生殖技术风险高、费用高,故应安全、有效、合乎伦理地使用排卵诱导,并在以患者为中心的多学科照护模式下将其作为一线干预。
要点
- 无其他不孕原因时,1型和2型无排卵患者排卵诱导可达80%排卵率、40%累积妊娠率且不良反应少。
- 辅助生殖技术风险高、费用高,而更简单、安全、廉价的药物排卵诱导可达到相当妊娠率。
- 作者强调排卵诱导应作为无排卵性生育力低下夫妇的一线干预,并置于以患者为中心的多学科照护模式中。
核心结论
- 作者主张在该人群中安全、有效、合乎伦理地使用排卵诱导,并辅以审慎的辅助生殖技术治疗。
- 作者强调排卵诱导应作为无排卵性生育力低下夫妇的一线干预,在以患者为中心的多学科照护模式中提供,并基于个体反应、特征和治疗偏好设有明确的辅助生殖技术升级路径。
研究设计与样本
- 本文为论述性文章,未报告系统检索范围或原始研究数据。
主要发现
- 在无其他不孕原因时,1型和2型无排卵患者行排卵诱导可达80%排卵率、40%累积妊娠率且不良反应少。
- 辅助生殖技术治疗伴随多种风险和高昂费用,而更简单、安全、廉价的药物排卵诱导可达到相当妊娠率,故难以论证前者的成本效益。
临床怎么用
- 作者主张将排卵诱导作为无排卵性生育力低下夫妇的一线干预,并在以患者为中心的多学科照护模式中提供。
- 作者主张基于个体反应、特征和治疗偏好,设有明确的升级至辅助生殖技术治疗的路径。
- 作者主张安全、有效、合乎伦理地使用排卵诱导,并辅以审慎的辅助生殖技术治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rapid advances in assisted reproductive technology have revolutionized fertility treatments for couples worldwide seeking a pregnancy. Although this is promising, concerns are emerging over the overuse of unnecessary assisted conception treatments, particularly among couples with anovulatory subfertility. Some experts are calling for the cessation of ovulation induction as the primary treatment of anovulatory subfertility in favour of more sophisticated assisted conception treatments. In the absence of other causes of subfertility, ovulation induction in patients with type 1 and type 2 anovulation disorders can achieve an up to 80% ovulation rate with a 40% cumulative pregnancy rate and few adverse effects. Considering the various risks and high costs associated with assisted reproductive technology treatments, it is hard to argue for their cost-effectiveness when simpler, safer and cheaper pharmacological ovulation induction could achieve comparable pregnancy rates. We argue here for the safe, effective and ethical use of ovulation induction in this population, supplemented by a judicious use of assisted conception treatments. We emphasize the essential role of ovulation induction as a first-line intervention for couples with anovulatory subfertility delivered within a patient-centred multidisciplinary care model and with a clear escalation pathway to use assisted reproductive technology treatments based on the person's response, characteristics and treatment preference.
引用
- Al Wattar BH, Talaulikar V. In praise of ovulation induction for the management of anovulatory subfertility. Reprod Biomed Online. 2023. PMID: 37198005. doi:10.1016/j.rbmo.2023.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。